Ufonia
Ufonia is a UK-based clinical AI company whose autonomous voice agent Dora conducts routine telephone-based patient consultations across healthcare pathways, primarily ophthalmology/cataract surgery, serving 22+ NHS organisations and expanding into the US market via academic medical center partnerships.
- Company typePrivate
- Founded2020
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Ufonia does
Ufonia is a UK-headquartered clinical AI company founded in 2020 by neurosurgeon Dr Nick de Pennington to automate routine patient telephone interactions in healthcare pathways. Its flagship product, Dora, is an autonomous voice-based clinical AI agent that conducts full telephone consultations with patients — covering pre-operative history taking, patient education, pre-op preparation, and post-operative follow-up — initially focused on ophthalmology/cataract surgery pathways and expanding into ENT and orthopaedics. The technology is built on a hybrid LLM and deterministic safety architecture with Retrieval Augmented Generation grounded in approved clinical guidelines, supported by two proprietary evaluation frameworks: MATRIX (multi-agent simulation for hazardous scenario detection) and ASTRID (RAG-based clinical question answering evaluation). Dora is a UKCA Class I Software as a Medical Device, MHRA-regulated, CQC-registered, and compliant with DCB0129/DCB0160 clinical safety standards.
The company operates a subscription-based enterprise SaaS model targeting NHS Trusts in the UK and US ophthalmology practices and health systems. As of early 2026, Dora has been deployed across 15+ NHS Trusts and 22+ NHS organisations, conducting 150,000+ autonomous clinical conversations with 110,000+ satisfaction responses collected and a documented patient satisfaction rate of 87.9% (NPS +56). Documented operational outcomes include a 167% increase in cataract follow-up capacity at Buckinghamshire Healthcare NHS Trust, 60% reduction in nurse calls at University Hospitals Leicester, and 1,150+ clinical hours released at Frimley Health NHS Foundation Trust.
Go-to-market is sales-led enterprise field sales, complemented by event-driven presence at major ophthalmology conferences (ASCRS, ARVO, ESCRS, AAO, Royal College of Ophthalmologists), clinical trial partnerships with academic medical centers, and a US Launch Partner Program. The company is expanding from the UK into the United States through a Delaware subsidiary (Ufonia Inc, Houston) with clinical trial sites at Dell Medical School and Baylor College of Medicine, ahead of a full commercial launch planned for ASCRS 2026. Cumulative disclosed funding includes SBRI Healthcare grants, a Series 1 round led by Wavemaker 360 with Octopus Ventures (September 2022), and investment from Qubit Health Capital (June 2024). The team is approximately 30 people, with about one-third from clinical backgrounds.
Ufonia firmographics
Firmographics- Name
- Ufonia
- Legal name
- Ufonia Ltd / Ufonia Inc
- Website
- https://ufonia.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ufonia is a UK-based clinical AI company whose autonomous voice agent Dora conducts routine telephone-based patient consultations across healthcare pathways, primarily ophthalmology/cataract surgery, serving 22+ NHS organisations and expanding into the US market via academic medical center partnerships.
- Ownership category
- akta.pro rank
Ufonia industry classification
Industry- Product category
- Healthcare AI / Clinical Conversation Automation
- akta.pro primary industry
- Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH)
Keywords
Where Ufonia is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Ufonia business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Healthcare AI Platform Subscription: Subscription-based model for access to Dora clinical AI agent platform deployed across healthcare systems. Pricing likely varies by practice size and call volume.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise Healthcare Practices |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Ufonia product offering
Product offeringCore offering
Ufonia develops Dora, an autonomous clinical AI voice agent that conducts telephone consultations with patients across cataract and broader care pathways. Dora automates routine clinical conversations including pre-operative history taking, patient education, pre-op preparation, and post-operative follow-up, deployed as a regulated medical device to NHS trusts and US health systems.
Product overview
Ufonia offers a single unified product called Dora, a clinical AI agent that conducts autonomous telephone consultations with patients. Dora is a UKCA Class I medical device focused primarily on ophthalmology/cataract care pathways. The core product handles the complete patient consultation lifecycle including pre-operative history taking, patient education, pre-op preparation, and post-operative follow-up. Supporting sub-products include MATRIX (safety simulation framework) and ASTRID (clinical question answering evaluation framework) which are internal evaluation tools rather than customer-facing offerings. Dora Advance represents the US market variant of the core product. The platform operates across fifteen NHS Trusts in the UK and is expanding to the US market.
Differentiator
Problem solved
Functional benefit
Brands
- Dora: Dora is Ufonia's clinical AI agent that conducts autonomous telephone conversations with patients for preoperative assessment, postoperative follow-up, triage, and patient education across healthcare pathways including ophthalmology.
Products and services
- Dora A clinical AI agent that conducts autonomous telephone consultations with patients, supporting cataract care pathways through history taking, patient education, pre-operative preparation, and post-operative follow-up. Voice-based conversational AI operating as a UKCA Class I medical device, deployed across NHS trusts in the UK.
- Dora Advance The US market version of Ufonia's clinical AI agent, featuring autonomous consultation capabilities adapted for US ophthalmology practices. In clinical trial phase with select US practices, with a Launch Partner Program for early access.
Quantifiable outcome
- 97.57% diagnostic accuracy for post-op cataract patients requiring clinical review
- +6 more outcomes
Companies that use Ufonia
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles2 records
Ufonia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature5 records
Ufonia partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered flagship, core and minor.
- Dell Medical School at University of Texas AustinflagshipClinical trial partnership marking Dora's first US deployment. First US trial call completed at Dell Medical School in December 2025. Pathway to broader US market entry with full launch planned at ASCRS 2026.
- Baylor College of MedicinecoreClinical trial site for Dora US clinical trials in ophthalmology. Dr Lauren Blieden serves as Principal Investigator.
- Texas Medical CentercoreWorld's largest medical ecosystem providing access to US healthcare market through Innovate UK Global Incubator Programme engagement.
- Innovate UK Global Incubator ProgrammecoreEnabled engagement with Texas Medical Center and access to world's largest medical ecosystem for US market entry.
- ABHI (Association of British HealthTech Industries)coreABHI US Accelerator trade visits to Austin created connection with Dell Medical Center for clinical trial partnership.
- Oxford University Hospitals NHS Foundation TrustcoreNHS trust partner and clinical trial site with Dr Aisling Higham as Consultant Ophthalmologist. Early deployment site for Dora.
- Moorfields Eye Hospital NHS Foundation TrustcoreNIHR-funded clinical trial for multilingual AI (800 patients, 10 languages including Polish, Bengali, Spanish) with University of York Centre for Assuring Autonomy.
- University of OxfordcoreAcademic collaborator on clinical AI safety research and evaluation frameworks. Co-author on Nature Medicine paper.
- University of YorkcoreCentre for Assuring Autonomy collaborator on ethics assurance case and multilingual AI clinical trial.
- DemDxminorCo-founded by Dr Mariane Melo before joining Ufonia. Clinical decision support system developed with Moorfields Eye Hospital collaboration.
- Imperial College Healthcare NHS TrustcoreNIHR-funded clinical trial site for cataract follow-up validation alongside Oxford University Hospitals.
- University College LondoncoreAcademic collaborator on clinical AI research and evaluation.
- Newcastle UniversitycoreAcademic collaborator on clinical AI research.
- Centre for Sustainable HealthcarecoreConducted environmental impact analysis showing Dora produces 50-100x less carbon than face-to-face consultations. Evaluation across 4 NHS sites.
- Health Innovation Oxford and Thames ValleycorePartner on multilingual AI clinical trial and focus groups with diverse communities including Turkish- and Polish-speaking populations.
Scale indicators12 records
Recent moves7 records
Expansion highlights7 records
Ufonia competitors and assessment
Company assessmentDirect peers
- Hippocratic AI: Hippocratic AI builds safety-focused LLM agents for healthcare, including patient-facing conversational interactions across clinical workflows. It is the closest analogue to Ufonia's autonomous clinical voice-agent model and competes for similar health system buyers.
- Suki: Suki is an AI clinical assistant that uses voice and ambient AI to reduce documentation and administrative burden for clinicians. While more documentation-focused, it shares Ufonia's voice-AI-for-clinicians thesis and overlapping health system buyer.
- Abridge: Abridge applies AI to clinical conversations, generating structured notes and engaging patients post-visit. It overlaps with Ufonia in using AI to automate clinical conversation workflows for healthcare systems, though focused on ambient documentation.
- Augmedix: Augmedix provides AI-powered ambient clinical documentation and patient interaction tools for healthcare providers. It overlaps with Ufonia in automating clinician-patient interactions using AI voice technology across health systems.
Emerging players
- Regard: Regard uses AI to analyze clinical data and surface diagnoses from patient charts, automating clinical review. It overlaps with Ufonia's clinical-decision-support layer and competes for the same hospital AI-safety conversation.
- Nabla: Nabla builds an AI medical assistant for clinicians including ambient documentation and patient communication. It shares Ufonia's voice-AI-for-clinicians and patient-engagement thesis across health systems.
- Notable: Notable applies AI to automate hospital workflows including patient outreach, intake, and follow-up. It overlaps with Ufonia's patient-communication automation layer, though focused on broader administrative workflows.
- DemDx: DemDx is a clinical decision support system co-founded by Ufonia's Clinical Trials Lead, originally developed with Moorfields Eye Hospital. It is a partial-overlap peer in AI-driven clinical reasoning for ophthalmology.
Regional players
- Cera: Cera is a UK-based digital health company using AI to automate home care visits and patient triage. It is a UK regional peer pursuing AI-driven patient communication and triage in adjacent care settings.
- Ada Health: Ada Health provides AI-driven symptom assessment and patient triage, with strong European health system presence. It is a regional peer in conversational AI for clinical triage and patient-facing interactions.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Ufonia social profiles
Digital presenceUfonia compliance and trust
Trust signalCompliance5 records
Ufonia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ufonia leadership team
Management profileNumber of profiles
Profiles16 records
Ufonia funding detail
Funding detailFunding overview
Funding rounds9 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ufonia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ufonia
What does Ufonia do?
Ufonia develops Dora, an autonomous clinical AI voice agent that conducts telephone consultations with patients across cataract and broader care pathways. Dora automates routine clinical conversations including pre-operative history taking, patient education, pre-op preparation, and post-operative follow-up, deployed as a regulated medical device to NHS trusts and US health systems.
Is Ufonia a public or private company?
Ufonia is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ufonia founded?
Ufonia was founded in 2020. It employs 11 to 50 people.
Where is Ufonia based?
Ufonia is headquartered in London, United Kingdom, in the Europe region.
How does Ufonia make money?
One revenue line is on record: healthcare AI Platform Subscription.
Who are Ufonia's main competitors?
Direct peers on record are Hippocratic AI, Suki, Abridge and Augmedix. Emerging players are Regard, Nabla, Notable and DemDx. Regional players are Cera and Ada Health.
Does Ufonia have an API?
No public API is recorded for Ufonia.
What industry is Ufonia in?
Ufonia's product category is Healthcare AI / Clinical Conversation Automation. Its primary akta.pro industry code is HLAHAJAH, Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics).